DOCSLIB.ORG

Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease Review Anti-cytokine biologic treatment beyond anti-TNF in Behçet’s disease A. Arida, P.P. Sfikakis First Department of Propedeutic Internal ABSTRACT and thrombotic complications (1-3). Medicine Laikon Hospital, Athens, Unmet therapeutic needs in Behçet’s Treatment varies according to type and University Medical School, Greece. disease have drawn recent attention to severity of disease manifestations. Cor- Aikaterini Arida, MD biological agents targeting cytokines ticosteroids, interferon-alpha and con- Petros P. Sfikakis, MD other than TNF. The anti-IL-17 anti- ventional immunosuppressive drugs, Please address correspondence to: body secukinumab and the anti-IL-2 such as azathioprine, cyclosporine-A, Petros P. Sfikakis, MD, receptor antibody daclizumab were not cyclophosphamide and methotrexate, First Department of Propedeutic superior to placebo for ocular Behçet’s and Internal Medicine, are used either alone or in combination Laikon Hospital, in randomised controlled trials, com- for vital organ involvement. During the Athens University Medical School, prising 118 and 17 patients, respec- last decade there has been increased use Ag Thoma, 17, tively. The anti-IL-1 agents anakinra of anti-TNF monoclonal antibodies in GR-11527 Athens, Greece. and canakinumab and the anti-IL-6 patients with BD who were refractory E-mail: [email protected] agent tocilizumab were given to iso- to conventional treatment or developed Received on June 7, 2014; accepted in lated refractory disease patients, who life-threatening complications (4, 5). revised form on September 17, 2014. were either anti-TNF naïve (n=9) or Anti-TNF treatment has been shown to Clin Exp Rheumatol 2014; 32 (Suppl. 84): experienced (n=18). No new safety be beneficial for the majority of these S149-S155. signals were reported. Although a po- patients (6, 7) but since unmet needs © Copyright CLINICAL AND tential for bias to report positive effects still exist reports on patients who have EXPERIMENTAL RHEUMATOLOGY 2014. and underreport negative cases may been treated with biologic agents tar- exist, Anakinra was partially effective, geting other cytokines are increasingly Key words: Behçet’s disease, whereas disease remission was noted appearing in the literature (8). biological treatment, anti-TNF agents, after canakinumab in some anti-TNF Herein, we critically discuss the po- cytokines, IL-1, IL-6, IL-17, IL-2 resistant patients. Tocilizumab ap- tential usefulness of the IL-1 receptor peared effective for neuro-Behçet’s, but antagonist anakinra, the anti-IL-1β an- not for mucocutaneous manifestations. tibodies canakinumab and gevokizum- Finally, in a pilot study of 7 patients ab and the anti-IL-6 receptor antibody with relapsing posterior uveitis re- Tocilizumab, which were given in the fractory to azathioprine and/or cyclo- first 33 patients with BD refractory to sporine, the anti-IL-1β antibody Ge- currently available treatment regimens. vokizumab was beneficial. Collectively, We also summarise the negative results it seems that IL-1 and IL-6 are prom- of the 2 randomised placebo-controlled ising targets in patients refractory or trials performed so far, in which the IL- intolerant to other regimens including 17 monoclonal antibody secukinumab anti-TNFs. However, controlled studies and the IL-2 receptor binding antibody are surely needed. daclizumab were tested for BD-associ- ated ocular inflammation. Introduction Behçet’s disease (BD) is a chronic im- Materials and methods mune-mediated systemic vasculitis with We searched the Medline/Pubmed da- severe morbidity and increased mortal- tabase for primary articles published ity. Although clinical manifestations of trough April 2014 reporting on the the disease may have great individual therapeutic use of biological agents variability, BD is characterised by re- targeting cytokines other than TNF in current oral and genital ulcers, pustular BD. Search terms included: Behçet’s skin lesions, arthritis, posterior uveitis in combination with cytokine, inter- attacks which lead to significant visual leukin, IL-1, IL-6, IL-17, IL-12/23, impairment or visual loss, neurologi- IL-2 biologics, monoclonal antibody, Competing interests: none declared. cal and gastrointestinal manifestations anakinra, canakinumab, gevokizumab, S-149 REVIEW Anti-cytokine treatment in Behçet’s disease / A. Arida & P.P. Sfikakis tocilizumab and ustekinumab, secuki- 5 of whom were subsequently treated endpoints in the secukinumab study numab, daclizumab. We included case also with canakinumab. Of the remain- were reduction of uveitis recurrence or reports, case series and research stud- ing 10 anti-TNF experienced patients, vitreous haze score during withdrawal ies, whereas systematic reviews, meta- 5 had been previously treated with In- of concomitant immunosuppressive analyses, comments and duplicate stud- fliximab (11, 14, 15, 17), 3 with adali- medication. Daclizumab was not found ies were excluded. Abstracts presented mumab (14, 17) and 2 with both these to be beneficial in comparison with in conferences were not considered. anti-TNF agents (13, 16). placebo for ocular complications of The use of IL-6 inhibitor tocilizumab BD in a total of 17 patients (9). From Results was described in 7 reports including 8 9 patients assigned to receive the study Two randomised double-blind placebo- patients (19-25), of whom only one was drug, none experienced a safety end- controlled trials were found, as well anti-TNF therapy naive (23), 4 had been point, but 2 discontinued prior to the as one open-label research pilot study treated with infliximab (19-22, 25), end of the study due to personal rea- (Table I) and 15 primary case reports or one had previously received both Inf- sons. Visual acuity remained stable in case-series (Tables II and III). The first liximab and adalimumab (22) and one all participants. Six daclizumab-treated randomised study, involving a total of – apart from anti-TNF antibodies – had patients experienced ocular attacks dur- 17 patients, focused on the efficacy and also been treated with anakinra (24). ing the study period requiring therapy, safety of daclizumab for ocular mani- We found only one report on the use of versus 4 receiving placebo, and the me- festations of BD (9). The second study ustekinumab (anti-IL12/23 antibody) in dian ocular attack rate was greater in the included 118 BD patients assigned to one psoriasis patient with concomitant daclizumab treatment group compared 3 treatment arms and aimed to explore BD who had not previously received to placebo. Moreover, there was greater the therapeutic effect and safety of any biological treatment (26). reduction of concomitant immunosup- secukinumab for posterior uveitis and pressants in patients receiving placebo panuveitis (10). Anti-TNF treatment naïve patients than daclizumab. There were 8 reports on the use of Both randomised controlled studies In the secukinumab trial 39 patients anti-IL-1 agents; 12 patients were involved patients with relapsing ocu- received 300mg/2 weeks, 40 received treated with anakinra (11-15), 5 were lar inflammation despite conventional 300mg/4 weeks and 39 patients re- treated with canakinumab after having treatment. Primary efficacy outcomes ceived placebo; there were more dis- received anakinra (14, 16, 17), and 7 in the daclizumab study were the num- continuations due to adverse events in patients described in the pilot study, ber of ocular attacks and an assessment the secukinumab treatment groups com- were treated with gevokizumab (18). of systemic immunosuppressive medi- pared to placebo group. Overall, 9% of All patients included in the pilot study cations required during the study, in- patients discontinued secukinumab be- were anti-TNF treatment naïve, as cluding the ability to taper concomitant cause of serious adverse events and the were 7 patients treated with anakinra, immunosuppressive therapy. Primary 3 most frequently reported events were Table I. Therapeutic results of a single infusion of the anti-IL1beta monoclonal antibody gevokizumab given for a unilateral relapse of posterior uveitis despite treatment with azathioprine and/or cyclosporine in 7 patients with Behçet’s disease, 4 of whom received a second injection (18). Gender, Previous treatment Concomitant Clinical outcome and maximum visual acuity (VA) change Outcome on follow-up to day 95 Age suspended at day 0 prednisolone after a single gevokizumab intravenous infusion (0.3mg/kg) dose (mg/d) M, 25 Azathioprine, 10 Almost complete resolution of hypopyon at day 1, Exacerbation at day 56 requiring Cyclosporine VA improvement at day 21 (20/20 from 20/63) a second infusion and response M, 37 Cyclosporine 7.5 Resolution of intraocular inflammation, VA stable (20/20) Exacerbation at day 56 requiring a second infusion and response F, 33 Azathioprine, 10 VA improvement at day 56 (20/100 from counting fingers 2m) Sustained response. Cyclosporine M, 37 Azathioprine, 5 Resolution of inflammation, VA improvement at day 4 Retinitis attack at day 25 requiring Cyclosporine (20/25 from 20/63) increased doses of prednisolone. M, 26 Azathioprine 5 Resolution of intraocular inflammation within 1 week. Cystoid macular edema at day 28 VA improvement at day 14 (20/25 from counting fingers 0.2m) requiring a second infusion and response M, 29 Azathioprine 20 Resolution of intraocular inflammation, VA improvement Exacerbation on day 49 requiring a at day 28 (20/20 from 20/32) second infusion and response. Another exacerbation at day 96 treated with corticosteroids M, 25 Azathioprine, 10 Incomplete resolution of cystoid macular edema, Beribulbar and intravitreal Cyclosporine VA stable at day 7 (20/100) triamcinolone at days 7 and 22. S-150 Anti-cytokine treatment in Behçet’s disease / A. Arida & P.P. Sfikakis REVIEW Table II. Results of treatment with biologic agents targeting IL-1, IL-6, or IL-12/23 for active Behçet’s in 9 anti-TNF treatment naïve patients. Gender, Previous Target clinical manifestations Biologic agent and Clinical outcome Follow up Age treatment concomitant treatment period Anti-IL1 Bilginer, F,17 Methotrexate, Mucocutaneous, arthritis, Anakinra 1mg/kg/d Remission for 6 months under 1 year 2010 Corticosteroids, secondary amyloidosis treatment.
Load more

Recommended publications
  • The Use of Biologic Agents in the Treatment of Oral Lesions Due to Pemphigus and Behçet's Disease: a Systematic Review
    Davis GE, Sarandev G, Vaughan AT, Al-Eryani K, Enciso R. The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review. J Anesthesiol & Pain Therapy. 2020;1(1):14-23 Systematic Review Open Access The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review Gerald E. Davis II1,2, George Sarandev1, Alexander T. Vaughan1, Kamal Al-Eryani3, Reyes Enciso4* 1Advanced graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 2Assistant Dean of Academic Affairs, Assistant Professor, Restorative Dentistry, Meharry Medical College, School of Dentistry, Nashville, Tennessee, USA 3Assistant Professor of Clinical Dentistry, Division of Periodontology, Dental Hygiene & Diagnostic Sciences, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 4Associate Professor (Instructional), Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA Article Info Abstract Article Notes Background: Current treatments for pemphigus and Behçet’s disease, such Received: : March 11, 2019 as corticosteroids, have long-term serious adverse effects. Accepted: : April 29, 2020 Objective: The objective of this systematic review was to evaluate the *Correspondence: efficacy of biologic agents (biopharmaceuticals manufactured via a biological *Dr. Reyes Enciso, Associate Professor (Instructional), Division source) on the treatment of intraoral lesions associated with pemphigus and of Dental Public Health and Pediatric Dentistry, Herman Ostrow Behçet’s disease compared to glucocorticoids or placebo. School of Dentistry of USC, Los Angeles, California, USA; Email: [email protected].
    [Show full text]
  • Old and New Challenges in Uveitis Associated with Behçet's Disease
    Journal of Clinical Medicine Review Old and New Challenges in Uveitis Associated with Behçet’s Disease Julie Gueudry 1,* , Mathilde Leclercq 2, David Saadoun 3,4,5 and Bahram Bodaghi 6 1 Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France 2 Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France; [email protected] 3 Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] 4 Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France 5 Biotherapy (CIC-BTi), Hôpital Pitié-Salpêtrière, AP-HP, F-75651 Paris, France 6 Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-AP-HP, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France; [email protected] * Correspondence: [email protected]; Tel.: +33-2-32-88-80-57 Abstract: Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage.
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Genentech Tocilizumab Letter of Authority June 24 2021
    June 24, 2021 Hoffmann-La Roche, Ltd. C/O Genentech, Inc. Attention: Dhushy Thambipillai Regulatory Project Management 1 DNA Way, Bldg 45-1 South San Francisco, CA 94080 RE: Emergency Use Authorization 099 Dear Ms. Thambipillai: This letter is in response to Genentech, Inc.’s (Genentech) request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for the emergency use of Actemra1 (tocilizumab) for the treatment of coronavirus disease 2019 (COVID-19) in certain hospitalized patients, as described in the Scope of Authorization (Section II) of this letter, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3). On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes coronavirus disease 2019 (COVID-19).2 On the basis of such determination, the Secretary of HHS on March 27, 2020, declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the Act (21 3 U.S.C. 360bbb-3), subject to terms of any authorization issued under that section. Actemra is a recombinant humanized monoclonal antibody that selectively binds to both soluble and membrane-bound human IL-6 receptors (sIL-6R and mIL-6R) and subsequently inhibits IL- 6-mediated signaling through these receptors.
    [Show full text]
  • Where Do Novel Drugs of 2016 Fit In?
    FORMULARY JEOPARDY: WHERE DO NOVEL DRUGS OF 2016 FIT IN? Maabo Kludze, PharmD, MBA, CDE, BCPS, Associate Director Elizabeth A. Shlom, PharmD, BCPS, SVP & Director Clinical Pharmacy Program Acurity, Inc. Privileged and Confidential August 15, 2017 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ◆ Identify orphan drugs and first-in-class medications approved by the FDA in 2016. ◆ Describe the role of new agents approved for use in oncology patients. ◆ Identify and discuss the role of novel monoclonal antibodies. ◆ Discuss at least two new medications that address public health concerns. Neither Dr. Kludze nor Dr. Shlom have any conflicts of interest in regards to this presentation. Privileged and Confidential 2016 NDA Approvals (NMEs/BLAs) ◆ Nuplazid (primavanserin) P ◆ Adlyxin (lixisenatide) ◆ Ocaliva (obeticholic acid) P, O ◆ Anthim (obitoxaximab) O ◆ Rubraca (rucaparib camsylate) P, O ◆ Axumin (fluciclovive F18) P ◆ Spinraza (nusinersen sodium) P, O ◆ Briviact (brivaracetam) ◆ Taltz (ixekizumab) ◆ Cinqair (reslizumab) ◆ Tecentriq (atezolizumab) P ◆ Defitelio (defibrotide sodium) P, O ◆ Venclexta (venetoclax) P, O ◆ Epclusa (sofosburvir and velpatasvir) P ◆ Xiidra (lifitigrast) P ◆ Eucrisa (crisaborole) ◆ Zepatier (elbasvir and grazoprevir) P ◆ Exondys 51 (eteplirsen) P, O ◆ Zinbyrta (daclizumab) ◆ Lartruvo (olaratumab) P, O ◆ Zinplava (bezlotoxumab) P ◆ NETSTPOT (gallium Ga 68 dotatate) P, O O = Orphan; P = Priority Review; Red = BLA Privileged and Confidential History of FDA Approvals Privileged and Confidential Orphan Drugs ◆FDA Office of Orphan Products Development • Orphan Drug Act (1983) – drugs and biologics . “intended for safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S.
    [Show full text]
  • Presenters: Philip R
    UC Davis Dermatology Online Journal Title Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Permalink https://escholarship.org/uc/item/8109j4cw Journal Dermatology Online Journal, 20(1) Authors Cohen, Philip R Kurzrock, Razelle Publication Date 2014 DOI 10.5070/D3201021241 License https://creativecommons.org/licenses/by-nc-nd/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Volume 20 Number 1 January 2014 Case Report Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma Philip R. Cohen, MD1 and Razelle Kurzrock, MD2 Dermatology Online Journal 20 (1): 1 1Division of Dermatology, University of California San Diego, San Diego, California; 2Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California San Diego—Moores Cancer Center, La Jolla, California. Correspondence: Philip R. Cohen, MD 10991 Twinleaf Court San Diego, CA 92131-3643 [email protected] Abstract Background: Anakinra is a recombinant form of interleukin-1 receptor antagonist. It is the drug of choice for Schnitzler syndrome and cryopyrin-associated periodic syndromes. It has also recently been demonstrated to have activity in the treatment of the non-Langerhans cell histiocytosis known as Erdheim-Chester disease. Purpose: To describe the activity of anakinra in a patient with co-existing lichen planus and Erdheim-Chester disease. Methods: A 43-year-old woman with progressive Erdheim-Chester disease presented for management of her night sweats and chills, systemic skeletal bone pain, and neurologic (diabetes insipidus) manifestations. She also had widespread cutaneous lichen planus.
    [Show full text]
  • Tocilizumab in Hospitalised Adults with Covid-19
    This document has been approved for use at [ ] USE OF TOCILIZUMAB IN HOSPITALISED ADULTS WITH COVID-19 INFORMATION FOR PATIENTS, FAMILIES AND CARERS This information leaflet contains important information about the medicine called tocilizumab when used in the treatment of COVID-19. WHAT IS THE POTENTIAL BENEFIT OF It is important you provide your formal consent TOCILIZUMAB FOR COVID-19? before receiving tocilizumab. You can always change your mind about treatment with Tocilizumab belongs to a group of medicines called tocilizumab and withdraw consent at any time. monoclonal antibodies. Monoclonal antibodies are proteins, which specifically recognise and bind to unique proteins in the body to modify the way the WHAT SHOULD THE DOCTOR KNOW immune system works. Tocilizumab has effects on BEFORE TOCILIZUMAB IS USED IN the immune system that may be useful in helping COVID-19? to reduce the effects of severe COVID-19. The doctor should know about: Tocilizumab has been approved in Australia to treat any other conditions including HIV or AIDs, some immune conditions such as arthritis, cytokine tuberculosis, diverticulitis, stomach ulcers, release syndrome and giant cell arteritis. The brand diabetes, cancer, heart problems, raised name is Actemra®. blood pressure or any nerve disease such as Recent clinical trials studying the effectiveness of neuropathy tocilizumab in COVID-19 have been analysed by previous allergic reactions to any medicine Australia’s National COVID-19 Clinical Evidence all medicines including over-the-counter and Taskforce. The Taskforce makes recommendations complementary medicines e.g. vitamins, about when tocilizumab is most likely to be minerals, herbal or naturopathic medicines effective in the treatment of COVID-19.
    [Show full text]
  • Biological Therapies for Atopic Dermatitis: an Update (Review)
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 1061-1067, 2019 Biological therapies for atopic dermatitis: An update (Review) DIANA DELEANU1-3 and IRENA NEDELEA1,2 1Allergology and Immunology Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400058 Cluj-Napoca; Departments of 2Allergy and 3Internal Medicine, ‘Professor Doctor Octavian Fodor’ Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania Received July 6, 2018; Accepted August 22, 2018 DOI: 10.3892/etm.2018.6989 Abstract. Severe atopic dermatitis, which affects both adults in low-income countries (3). Furthermore, the past decades and children, is a debilitating disorder with a significant decline brought a 2-3-fold increase in prevalence in industrialized of patients' quality of life. Although aetiopathogenic factors countries (3). Generally AD onset is in early childhood, as are currently a topic of study and interpretation, the main one of the first steps of the ‘atopic march’, which describes the features of atopic eczema are skin barrier disturbance and natural history of atopic manifestations, and it is character- immune dysregulation. Severe refractory disease that fails to ized by xerotic skin and acute flare-ups of intensely pruritic improve with conventional therapy may benefit from biologic eczematous lesions (4). Recent studies recognize a predilection therapy. Progress in understanding immunopathology of atopic of AD for persistence in adulthood, with a lifetime prevalence dermatitis have allowed identification of therapeutic molecular accounting for 34.1% (5). Early onset, allergic rhinitis and targets in the field of biological therapy. We reviewed the hand eczema in childhood are high-risk factors for persistent different biological treatments with a focus on novel targeted AD (5).
    [Show full text]
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection
    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
    [Show full text]
  • Clinical Research in Adult Vasculitis
    Clinical research in adult vasculitis Calgary – October 8th, 2015 Disclosures • Consulting and speaker fees – Hoffmann-La Roche – BMS • Advisory boards – Hoffmann-La Roche – GSK • Educational subventions (CanVasc) – Hoffmann-La Roche – Terumo BCT – Abbott Immunology – BMS – Pfizer-Amgen – Janssen-Cilag – Euroimmun Learning Outcomes 1. To review some of the existing international research networks and groups 2. To review some of the ongoing studies on adult vasculitis, in which Canada participates 3. To discuss issues pertinent to various specialties (internal medicine, rheumatology, nephrology and respirology) including research collaboration in Canada 4. To be aware of CanVasc and its activities in adult vasculitis 2012 revised Chapel hill nomenclature Jennette et al. Arthritis Rheum. 2013 Treatment of severe GPA/MPA CYCLOPHOSPHAMIDE AZATHIOPRINE 2 mg/kg/d 15 mg/kg (d1,14,28 then q3wk) METHOTREXATE 0.3 mg/kg/wk ? LEFLUNOMIDE 20 mg/d 2 mg/kg/d MYCOPHENOLATE MOFETIL 2 g/d Rituximab 500mg q6m RITUXIMAB 375mg/m2 x4 ? + Corticosteroids R 3 - 6 months > 18 months INDUCTION MAINTENANCE + adjuvant/prophylactic measures: cotrimoxazole, osteoporosis treatment, etc DCVAS Study – ACR/EULAR diagnostic and classification criteria for vasculitis – Number of centres: 118 This project anticipates to produce the following: • 1) A new validated set of classification criteria for the primary systemic vasculitides. • 2) A validated set of diagnostic criteria for the primary systemic vasculitides. DCVAS Study • How will the final revisions differ from the current ACR criteria? • The main differences will be: • Use modern diagnostic tests (e.g. ANCA, use of diagnostic ultrasound for GCA), new tools of disease activity (BVAS) and tools measuring vasculitis damage (VDI) to further refine the criteria.
    [Show full text]
  • Ilaris Canakinumab for Systemic Juvenile Idiopathic Arthritis SJIA
    Subject: Ilaris (canakinumab) for Systemic Juvenile Original Effective Date: 4/24/2015 Idiopathic Arthritis (SJIA) Policy Number: MCP-246 Revision Date(s): Review Date(s): 12/15/2016; 6/22/2017 DISCLAIMER This Medical Policy is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina medical coverage policy (MCP) document and provide the directive for all Medicare members. SUMMARY This policy addresses the coverage of Ilaris (canakinumab) for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) when appropriate criteria are met.
    [Show full text]
  • Tocilizumab in the Treatment of Severe and Refractory Parenchymal Neuro
    TAB0010.1177/1759720X20971908Therapeutic Advances in Musculoskeletal DiseaseJ Liu, D Yan 971908research-article20202020 Therapeutic Advances in Musculoskeletal Disease Case Series Ther Adv Musculoskel Dis Tocilizumab in the treatment of severe and 2020, Vol. 12: 1–8 DOI:https://doi.org/10.1177/1759720X20971908 10.1177/ refractory parenchymal neuro-Behçet’s 1759720X20971908https://doi.org/10.1177/1759720X20971908 © The Author(s), 2020. Article reuse guidelines: syndrome: case series and literature review sagepub.com/journals- permissions Jinjing Liu* , Dong Yan*, Zhimian Wang, Yunjiao Yang, Shangzhu Zhang, Di Wu, Lingyi Peng, Zhichun Liu and Wenjie Zheng Abstract Correspondence to: Objectives: This study aimed to investigate the efficacy and safety of tocilizumab (TCZ) in Wenjie Zheng severe and refractory parenchymal neuro-Behçet’s syndrome (p-NBS). Department of Rheumatology and Clinical Methods: We retrospectively analyzed five patients with p-NBS treated with TCZ in our center Immunology, Peking Union between 2013 and 2020, and six cases from literature research with the index terms “neuro- Medical College Hospital, Chinese Academy of Behçet’s syndrome” and “tocilizumab” on PubMed NCBI. Medical Sciences & Peking Union Medical Results: A total of 11 patients with p-NBS were enrolled (5 males, 6 females), with a mean College, Key Laboratory of age of 34.5 ± 8.0 years at the onset. All the patients had parenchymal neurological lesions, Rheumatology and Clinical Rheumatology, Ministry six patients (54.5%) suffered from multiple lesions, and nine patients (81.8%) were disabled. of Education, National Clinical Research Center Before TCZ administration, all the patients had failed conventional therapy, eight patients for Dermatologic and (72.7%) received two or more immunosuppressants, and five patients showed insufficient Immunologic Diseases, No.
    [Show full text]